Bone MicroRNA in CKD Study
Research type
Research Study
Full title
Understanding the Role of MicroRNAs in Renal Osteodystrophy in Advanced Chronic Kidney Disease Patients
IRAS ID
346112
Contact name
Syazrah Salam
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
People living with severe chronic kidney disease (CKD) have high risk of breaking their bone (fracture). This risk is around 2.5 times higher in people with severe CKD and 4 times higher in dialysis patients compared to people without CKD. Bone fracture causes pain, immobility and can lead to death. The NHS spends £4.4 billion every year for treatment of fractures; with treatment costs in the year following fracture ranging from £861 (for every wrist fracture) to £8,235 (for every hip fracture). Patients with high risk of fracture should be treated to prevent bone fractures but this is not yet possible in people living with severe CKD.
The adult skeleton undergoes a lifelong process of removing old/damaged bone and replacing it with new/stronger bone. This process is also known as bone turnover. It becomes slower or faster in severe CKD than in healthy bone, likely resulting in weaker bone and making it more likely to break. The cause for this abnormal bone removal/replacement process is poorly understood; thus, there is no proven treatment to prevent bone fracture in this patient group.
MicroRNAs are chemicals that control many processes in the body, including bone. These microRNAs can be measured in the blood and may help us to identify the bone processes affected by CKD. This will focus our attention on potential treatments which restore those processes in order to prevent bone fracture.
REC name
London - London Bridge Research Ethics Committee
REC reference
24/PR/1242
Date of REC Opinion
15 Oct 2024
REC opinion
Favourable Opinion